Long-term follow-up for patients who received REACT injections for kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the long-term safety and effects of gelatin-hydrogel formulation REACT injections on renal function in participants with chronic kidney disease (CKD). Up to 80 participants who previously received REACT in earlier clinical trials will be monitored over a period of five years through a combination of in-clinic and phone visits. The study focuses on evaluating the outcomes of these injections administered 3 to 6 months apart, specifically looking at their impact on kidney health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.

Exclusion Criteria:

* The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.

Where it's running

• Boise Kidney & Hypertension Institute
  Meridian, Idaho, United States Recruiting

Study contacts

• Study coordinator: Beth Hilburger
• Email: info@prokidney.com
• Phone: 336-999-7031

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding Diabetic Kidney Disease in Patients with Type 2 Diabetes

  This study is trying to understand how kidney disease affects people with Type 2 diabetes and macroalbuminuria by looking at their kidney samples and other health markers over 20 years to improve treatment options.

  Recruiting at 13 sites Herlev Hospital · Skejby, Aarhus and 12 other locations · NCT04916132

• Assessing the impact of KidneyIntelX on managing chronic kidney disease in diabetes patients

  This study tests if the KidneyIntelX tool can help doctors better manage kidney health in people with Type 2 diabetes and chronic kidney disease.

  Recruiting Renalytix AI, Inc. · New York, New York · NCT04802395

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Impact of TAVR on kidney function in people with aortic valve disease

  This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, RM · NCT07626710

• Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs

  This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.

  Recruiting Odense University Hospital · Odense · NCT07511283

• MTX-439 safety test in healthy adults and adults with diabetic kidney disease

  This phase 1 study tests MTX-439 in healthy adults and adults with diabetic kidney disease to see if it is safe and how the body handles it.

  Recruiting Phase 1 Mediar Therapeutics · Melbourne, Victoria · NCT07473323

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.